ORPHAN AND ULTRA-ORPHAN TECHNOLOGIES: EUROPEAN AND AUSTRALIAN PAYER PERCEPTIONS

被引：0

作者：

Hogue, S. ^{[1
]}

Brogan, A. P. ^{[1
]}

Croft, E. ^{[2
]}

机构：

[1] RTI Hlth Solut, Res Triangle Pk, NC USA

[2] RTI Hlth Solut, Manchester, Lancs, England

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 07期

关键词：

D O I：

10.1016/j.jval.2015.09.2027

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PSY127

引用

下载

页码：A681 / A681

页数：1

共 50 条

[21] The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
Y. Schuller
C. E. M. Hollak
M. Biegstraaten
Orphanet Journal of Rare Diseases, 10
[22] FDA approves ultra-orphan drug on a 4-patient trial
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (10) : 669 - 669
[23] SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES OF ULTRA-ORPHAN THERAPIES
Aggarwal, S.
Topaloglu, H.
VALUE IN HEALTH, 2016, 19 (03) : A247 - A247
[24] FDA approves ultra-orphan drug on a 4-patient trial
Asher Mullard
Nature Reviews Drug Discovery, 2015, 14 : 669 - 669
[25] THE SMC ULTRA-ORPHAN FRAMEWORK: 3-YEAR REPORT CARD
Macaulay, R.
VALUE IN HEALTH, 2022, 25 (12) : S344 - S344
[26] Patient-based evidence: its role in decision making on end-of-life, orphan, and ultra-orphan medicines
Hems, Sharon
Taylor, Louise
Jones, Jan
Holmes, Eileen
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2023, 39 (01)
[27] IS HYPERAMMONEMIC CRISIS IN INBORN ERRORS OF METABOLISM AN ULTRA-ORPHAN DISEASE? A LITERATURE REVIEW
Wijaya, K.
VALUE IN HEALTH, 2022, 25 (12) : S223 - S224
[28] Enzyme replacement therapy in orphan and ultra-orphan diseases - The limitations of standard economic metrics as exemplified by Fabry-Anderson disease
Moore, David F.
Ries, Markus
Forget, Evelyn L.
Schiffmann, Raphael
PHARMACOECONOMICS, 2007, 25 (03) : 201 - 208
[29] Enzyme Replacement Therapy in Orphan and Ultra-Orphan DiseasesThe Limitations of Standard Economic Metrics as Exemplified by Fabry-Anderson Disease
David F. Moore
Markus Ries
Evelyn L. Forget
Raphael Schiffmann
PharmacoEconomics, 2007, 25 : 201 - 208
[30] ANALYSIS OF THE ULTRA-ORPHAN DRUGS APPROVED BY THE FDA IN THE PERIOD 1983-2014
Thumar, R.
Seoane-Vazquez, E.
Mantus, D.
Tyrrell, B.
VALUE IN HEALTH, 2016, 19 (03) : A255 - A255

← 1 2 3 4 5 →